Classer les publications sur l'année
-
Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.
SARAUX A, COMBE B, FAGNANI F, CUKIERMAN G, BRU I, JOUBERT J.-M , SCHULLER J.-C, MASSOL J, FLIPO R.-M
Clinical and Experimental Rheumatology ; 2020(Online)
-
Ăconomie de la santĂ©
Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.
POLACK B, TROSSAĂRT M, COUSIN M, BAFFERT S, PRUVOT A, GODARD C.
Haemophilia ; 2020;27(1)e1-e11
-
Santé publique
Expérimentation de la télé-expertise en cardiologie en Pays de la Loire.
HERAULT T, DONIO V, COUROUVE L, CAILLARD J.-B.
Santé publique ; 2019;31(6):789-796
-
Biométrie et Analyses de bases de données/SNDS
Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database
EMERY C, TORRETON E, DEJAGER S, LEVY-BACHELOT L, BINEAU S, DETOURNAY B.
Diabetes Ther ; 2020;11(2):535-548
-
Santé publique
Evaluation en éducation thérapeutique.
SIMON D, DETOURNAY B.
Education Thérapeutique. Prévention et maladies chroniques Issy les Moulineaux, Elsevier Masson Ed. Collection Abrégés 4Úme édition revue et augmentée ; 2020;407-420
-
Biométrie et Analyses de bases de données/SNDS
Profile of Women Initiated on Denosumab and Pattern of Use in a Restricted Postmenopausal Osteoporosis Indication: A French Database Analysis Over the Period 2013-2014.
EMERY C, GOURMELEN J, FAGNANI F, SUZAN F, DESAMERICQ G, FARDELLONE P.
Adv Ther ; 2019;36(4),969-975
-
Santé publique
Prise en charge précoce des psychoses émergentes en France. Recensement, description des activités et besoins en 2018.
LECARDEUR L, MEUNIER-CUSSAC S, GOZLAN G, DUBURCQ A, COUROUVE L, KREBS M-O.
LâInformation psychiatrique ; 2020;96(7),569-576
-
Pharmaco-Epidémiologie
Mepolizumab in a population with severe osinophilic asthma and corticosteroid dependence: results from French early access programme
TAILLE C, CHANEZ P, DEVOUASSOUX G, DIDIER A, PISON C, GARCIA G, CHARRIOT J, BOUEE S, GRUBER A, PRIBIL C, BOURDIN A, HUMBERT M.
Eur Respir J ; 2020;55(6)
-
Pharmaco-Epidémiologie
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study
GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C.
Future Oncol ; 2020;16(16),1115-1124
-
Biométrie et Analyses de bases de données/SNDS
Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.
EMERY C, TORRETON E, BRIERE JB, THOMAS EVERS T, FAGNANI F.
J Med Econ ; 2020;23(5):513-520
-
AutresSanté publique
The management of emergency hospital visits for inflammatorybowel diseases: A French national expert consensus report
HEBUTERNE X, PEYRIN-BIROULET L, HAUSFATER P.
Therapie ; 2020;52(4),420-426
-
Autres
Télésurveillance et expérimentations ETAPES. Quelle pérennité aprÚs 2021 : quel modÚle organisationnel et financement ?
LE DOUARIN Y, TRAVERSINO Y, GRACIET A, JOSSERAN A, ET LES PARTICIPANTS DE LA TABLE RONDE « SANTE ET ECONOMIE » DES ATELIERS DE GIENS XXXV, BRIAC BILI A, BLAISE L, CHATELLIER G, COULONJOU H, DELVAL C, DETOURNAY B, DURAND ZALESKI I, FOREST J, DAIDANI N, VANDENBERGUE J.
Therapies ; 2020;75(1),29-42
-
Santé publique
The management of emergency hospital visits for inflammatorybowel diseases: A French national expert consensus report.
HEBUTERNE X, PEYRIN-BIROULET L, HAUSFATER P.
Digestive and Liver Disease ; 2019
-
Ăconomie de la santĂ©
Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
HEQUET D, HUCHON C, SOILLY AL, ASSELAIN B, BERSENEFF H, TRICHOT C, COMBES A, ALVES K, NGUYEN T, ROUZIER R, BAFFERT S.
PLoS One ; 2019;14(7)
-
Santé publique
Exposure of adults to extremely low frequency magnetic field in France: results of the EXPERS study.
MAGNE I, SOUQUES M, COUROUVE L, DUBURCQ A, REMY E, CABANES PA.
Radioprotection ; 2020;55(1),39-50
  Â